Heart failure drug verquvo under Real-World safety watch in korea
NCT ID NCT06148935
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tracks 1,350 Korean adults with chronic heart failure who are prescribed Verquvo as part of their usual care. Researchers will monitor side effects and heart-related events over up to 12 months to see how safe and effective the drug is in everyday practice. No experimental treatments are given—just observation of routine medical care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many Locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.